Pluristem Therapeutics Inc (PSTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pluristem Therapeutics Inc (PSTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH82120D
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Pluristem Therapeutics Inc (Pluristem) is a clinical-stage biotherapy company that focuses on the development of placental-derived cell therapies. Its PLacental eXpanded (PLX) cells are adherent stromal cells that can be administered to patients without tissue or genetic matching. The company's product pipeline includes PLX-PAD for critical limb ischemia (CLI), intermittent claudication (IC), orthopaedic conditions, pulmonary arterial hypertension and women's health; PLX-Immune for kidney, colorectal, breast, lung, muscle, skin and liver cancers; and PLX-R18 for hematological system and acute radiation syndrome (ARS). The company harnesses its proprietary 3D cell expansion platform technology for developing its cell therapies. It works in partnership with medical, pharmaceutical and academic institutions to develop its product portfolio. Pluristem is headquartered in Haifa, Israel.

Pluristem Therapeutics Inc (PSTI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Pluristem Therapeutics Enters into Co-Development Agreement with Thermo Fisher Scientific 12

Pluristem Therapeutics Enters into Co-Development Agreement with US Department of Defense and US Army Medical Research Institute of Chemical Defense 13

Pluristem Enters into Agreement with Tel Aviv Sourasky 14

Pluristem Therapeutics to Enter into Agreement with New York Blood Center 15

Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 16

Pluristem Enters into MoU with Fukushima Medical University 17

Pluristem Therapeutics Plans to Enter into Agreement for PLacental eXpanded (PLX) Cell Therapies 18

Pluristem Therapeutics Enters Into Distribution Agreement With Fisher BioServices 19

Licensing Agreements 20

Pluristem Therapeutic Enters into Licensing Agreement with TES Holdings 20

Pluristem Enters Into Licensing Agreement With Cha Bio & Diostech For Placental Expanded Cells 21

Pluristem Therapeutics Plans To Enter Licensing Agreement For PLX-PAD 22

Equity Offering 23

Pluristem Therapeutics Raises USD1 Million in Public Offering of Shares 23

Pluristem Therapeutics Raises USD15.1 Million in Public Offering of Shares 24

Pluristem Therapeutics Raises USD17.3 Million in Public Offering of Shares and Warrants 25

Pluristem Therapeutics Raises USD17 Million in Private Placement of Units 27

Pluristem Therapeutics Files Registration Statement For Public Offering Of Common Stock For USD 95 Million 28

Pluristem Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For USD 36.5 Million 29

Pluristem Therapeutics Inc-Key Competitors 31

Pluristem Therapeutics Inc-Key Employees 32

Pluristem Therapeutics Inc-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

Sep 27, 2018: Pluristem Reports Fiscal 2018 Fourth Quarter Results and Provides Corporate Update 34

May 10, 2018: Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights 35

Feb 07, 2018: Pluristem Issues Letter to Shareholders 36

Nov 14, 2017: Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights 38

Sep 11, 2017: Pluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights 40

May 22, 2017: Pluristem Provides Shareholder Update on Corporate and Clinical Developments 42

Feb 13, 2017: Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook 44

Corporate Communications 46

Jun 14, 2018: Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results 46

Mar 29, 2017: Pluristem Launches Co-CEO Structure and Appoints New CFO 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

List of Figures

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pluristem Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Pluristem Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pluristem Therapeutics Enters into Co-Development Agreement with Thermo Fisher Scientific 12

Pluristem Therapeutics Enters into Co-Development Agreement with US Department of Defense and US Army Medical Research Institute of Chemical Defense 13

Pluristem Enters into Agreement with Tel Aviv Sourasky 14

Pluristem Therapeutics to Enter into Agreement with New York Blood Center 15

Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 16

Pluristem Enters into MoU with Fukushima Medical University 17

Pluristem Therapeutics Plans to Enter into Agreement for PLacental eXpanded (PLX) Cell Therapies 18

Pluristem Therapeutics Enters Into Distribution Agreement With Fisher BioServices 19

Pluristem Therapeutic Enters into Licensing Agreement with TES Holdings 20

Pluristem Enters Into Licensing Agreement With Cha Bio & Diostech For Placental Expanded Cells 21

Pluristem Therapeutics Plans To Enter Licensing Agreement For PLX-PAD 22

Pluristem Therapeutics Raises USD1 Million in Public Offering of Shares 23

Pluristem Therapeutics Raises USD15.1 Million in Public Offering of Shares 24

Pluristem Therapeutics Raises USD17.3 Million in Public Offering of Shares and Warrants 25

Pluristem Therapeutics Raises USD17 Million in Private Placement of Units 27

Pluristem Therapeutics Files Registration Statement For Public Offering Of Common Stock For USD 95 Million 28

Pluristem Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For USD 36.5 Million 29

Pluristem Therapeutics Inc, Key Competitors 31

Pluristem Therapeutics Inc, Key Employees 32

Pluristem Therapeutics Inc, Subsidiaries 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Pluristem Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17848
Site License
USD 500 INR 35695
Corporate User License
USD 750 INR 53543

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com